Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 6/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 4/20 | 0.41 |
| ▸ | NPC1 | O15118 | 5/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | HTT | P42858 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | ESRRG | P62508 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.40 |
| ▸ | MIF | P14174 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20202546 | 0.86 | RAB9A (0.48) | RAB9AALDH1A1MAPTNPC1SMN1; SMN2 | |
| SCHEMBL20185549 | 0.83 | RAB9A (0.46) | RAB9AALDH1A1HPGDMAPTNPC1 | |
| SCHEMBL20185551 | 0.83 | RAB9A (0.46) | RAB9AALDH1A1HPGDMAPTNPC1 | |
| SCHEMBL11046721 | 0.72 | RAB9A (0.43) | RAB9AALDH1A1HPGDNPC1SMN1; SMN2 | |
| SCHEMBL11046718 | 0.72 | RAB9A (0.43) | RAB9AALDH1A1HPGDNPC1SMN1; SMN2 | |
| SCHEMBL11046726 | 0.72 | RAB9A (0.43) | RAB9AALDH1A1HPGDNPC1SMN1; SMN2 | |
| SCHEMBL20583674 | 0.70 | NPC1 (0.43) | RAB9AALDH1A1MAPTNPC1SMN1; SMN2 | |
| SCHEMBL20583676 | 0.70 | NPC1 (0.43) | RAB9AALDH1A1MAPTNPC1SMN1; SMN2 | |
| SCHEMBL13605085 | 0.69 | MAPT (0.63) | RAB9AALDH1A1HPGDMAPTSMN1; SMN2 | |
| SCHEMBL20339566 | 0.69 | L3MBTL1 (0.56) | RAB9AALDH1A1MAPTNPC1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3302486-B1 | DIHYDROPYRAZOLOPYRIMIDINONE COMPOUNDS AS PDE2 INHIBITORS | MERCK SHARP & DOHME (US) | 2020-09-30 | — | — | EP | disclosed |
| US-10174037-B2 | Dihydropyrazolopyrimidinone compounds as PDE2 inhibitors | MERCK SHARP & DOHME CORP. (US) | 2019-01-08 | — | — | US | disclosed |
| US-20180148453-A1 | DIHYDROPYRAZOLOPYRIMIDINONE COMPOUNDS AS PDE2 INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2018-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180148453-A1 | DIHYDROPYRAZOLOPYRIMIDINONE COMPOUNDS AS PDE2 INHIBITORS | PDE12, PDE2A, PDE4D | RAB9A 700/4885ALDH1A1 635/4885HPGD 58/4885 |
| US-10174037-B2 | Dihydropyrazolopyrimidinone compounds as PDE2 inhibitors | PDE12, PDE2A, PDE4D | RAB9A 700/4885ALDH1A1 635/4885HPGD 58/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.